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The discovery of new chemotypes to feed the pipeline of
antimalarial drugs remains a constant challenge, particu-
larly in light of emerging resistance to current therapies.
Recently, phenotypic screenings have been successfully
used for antimalarial hit generation where the biological
target(s) may often not be clearly identified. To catalyse
malaria research by both filling the pipeline and having
a better understanding of ligand-target relationships, a
unique screening tool has been elaborated: the Malaria
Box.
The Malaria Box is a set composed of 400 commer-
cially available chemical entities derived from a selection
of more than 20,000 hits from the screening of corporate
and academic libraries [1-3]. The originality of the
Malaria Box relies in its composition of 200 lead-like and
200 probe-like compounds that have confirmed activity
on blood-staged Plasmodium falciparum and that have
been assessed for cytotoxicity. Lead-like compounds
commensurate with oral absorption and the presence of
known toxicophores has been reviewed. Conversely
probe-like compounds are intended to represent the
broadest cross-section of structural diversity.
Significantly, the scope of the Malaria Box goes beyond
the Malaria field as active compounds may have utility in
other parasitic or neglected diseases. It is well-documented
that artemisinin was initially discovered from helminth
research and is currently a gold standard drug against
Malaria. Also, the presence of orthologues of various
molecular targets may lead to new therapeutic applications
in orphan diseases or for example oncology. Ultimately,
the data collection resulting from the Malaria Box would
enable the community to better understand similarities
and differences between parasite diseases or orphan dis-
eases by mining data sets that were previously considered
separately [4].
Herein we disclose the selection process applied to
assemble the Malaria Box as well a preliminary results.
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